Maze Therapeutics, Inc. · Healthcare · Biotechnology
Scores & Status Key
AI Summary Scores: Intraday / Swing / Long scores are synthesized from multi-factor analysis for each timeframe. They summarize current conditions discussed in the report and do not constitute trading recommendations.
Intraday Trend Score: A 0–100 composite from the Trend Explorer™ analytics engine used for ranking and comparison. It describes current conditions and is not a forecast.
Trend Status: A rules-based label (Bullish / Mixed / Bearish) derived from signal confluence (trend structure, momentum, and positioning). It indicates alignment, not expected return.
Last
$45.59
−$0.25 (−0.54%) 4:00 PM ET
Prev closePrevC$45.84
OpenOpen$45.49
Day highHigh$46.45
Day lowLow$44.60
VolumeVol375,196
Avg volAvgVol488,518
On chart
Interval
Intervals apply to 1D & 5D.
Intervals apply to 1D & 5D.
Scale: Linear
Overlays
Panels
Style
Scale: Linear
Presets
Tools
Tickers only (no ^ indexes). Add up to 5.
Mkt cap
$2.19B
P/E ratio
-3.55
FY Revenue
$2.50M
EPS
-12.83
Gross Margin
100.00%
Sector
Healthcare
AI report sections
MIXED
MAZE
Maze Therapeutics, Inc.
Maze Therapeutics exhibits a steep upward price trajectory over the past six months supported by multiple bullish technical signals near the top of its 52-week range. At the same time, fundamentals show minimal revenue, very large operating losses, and deeply negative cash flow margins, paired with elevated valuation multiples. Short interest and intraday short volume are non-trivial, indicating some skepticism and potential volatility despite a generally constructive news backdrop.
AI summarized at 2:21 PM ET, 2026-01-20
AI summary scores
INTRADAY:63SWING:71LONG:32
Volume vs average
Intraday (cumulative)
−7% (Below avg)
Vol/Avg: 0.93×
RSI
52.32(Neutral)
Neutral (40–60)
0255075100
MACD momentum
Intraday
+0.01 (Strong)
MACD: 0.03 Signal: 0.03
Short-Term
-0.24 (Weak)
MACD: 0.69 Signal: 0.93
Long-Term
-0.19 (Weak)
MACD: 1.81 Signal: 2.00
Intraday trend score
41.61
LOW30.61HIGH54.61
Latest news
MAZE•7 articles•Positive: 7Neutral: 0Negative: 0
PositiveThe Motley Fool• Adé Hennis
Maze Therapeutics Chief Medical Officer Sells 15K Shares As Company's Stock Continues to Surge
Harold Bernstein, Chief Medical Officer of Maze Therapeutics, exercised and sold 15,000 shares for approximately $690,300 on February 2, 2026, fully divesting his direct ownership. The sale was part of a pre-arranged 10b5-1 trading plan and should not concern investors. Despite the insider sale, Bernstein retains nearly 300,000 stock options, and the company continues to be viewed as a strong buy by Wall Street analysts with strong clinical trial progress.
MAZEinsider tradingstock optionsbiotechnologyclinical trialskidney diseaseIPO10b5-1 trading plan
Sentiment note
Despite the insider share sale, the article emphasizes that this transaction should not concern investors as it was pre-planned. The company is described as 'flourishing,' has posted 284% one-year price growth, is widely considered a 'strong buy' by Wall Street analysts, and continues to advance in clinical trials for multiple medicines targeting kidney disease, cardiovascular, and metabolic conditions.
PositiveThe Motley Fool• Adé Hennis
Maze Therapeutics SVP Sells 5,000 Shares Amid Historic First Year for the Company's Stock
Amy Bachrodt, SVP of Finance at Maze Therapeutics, sold 5,000 shares for approximately $227,612 on January 22, 2026, as part of a Rule 10b5-1 trading plan. This transaction occurs after the company's stock surged 157% in 2025, its first year as a public company. While the strong performance is notable, analysts suggest investors should watch for potential short-term drawdowns, though the company's long-term prospects remain promising as it advances clinical trials for kidney and metabolic disease treatments.
MAZEinsider tradingstock saleIPO performancebiopharmaceuticalclinical trialsRule 10b5-1 trading plan
Sentiment note
The company achieved exceptional first-year stock performance with a 157% surge in 2025 following its IPO. The company is advancing to later clinical stages for medicines targeting kidney and metabolic diseases, which are expected to generate significant revenue. While the insider sale may suggest some caution, it was executed through a pre-planned trading arrangement rather than indicating loss of confidence. Long-term prospects remain promising.
PositiveGlobeNewswire Inc.• Na
Maze Therapeutics to Participate in the 44th Annual J.P. Morgan Healthcare Conference
Maze Therapeutics announced that CEO Jason Coloma will present at the 44th Annual J.P. Morgan Healthcare Conference on January 12, 2026. The clinical-stage biopharmaceutical company is developing small molecule precision medicines for kidney and metabolic diseases, with lead programs MZE829 (Phase 2 for APOL1-mediated kidney disease) and MZE782 (advancing to Phase 2 for PKU and chronic kidney disease).
MAZEbiopharmaceuticalprecision medicinekidney diseasemetabolic diseaseclinical trialJ.P. Morgan Healthcare ConferenceMZE829
Sentiment note
The company is advancing its pipeline programs to Phase 2 development and securing a presentation slot at a major industry conference, indicating progress in drug development and investor engagement. The announcement highlights clinical advancement of lead candidates for significant disease indications.
PositiveGlobeNewswire Inc.• Maze Therapeutics
Maze Therapeutics Appoints Industry Veteran Hervé Hoppenot as Chairman of the Board of Directors
Maze Therapeutics appointed Hervé Hoppenot as Chairman of its Board of Directors, succeeding Charles Homcy. Hoppenot brings over three decades of biotech leadership experience and previously served as CEO of Incyte Corporation.
Appointed an experienced industry leader, raised $150 million in private placement, and has promising clinical-stage drug candidates
PositiveInvesting.com• Chris Markoch
Biotech Breakouts: 3 Stocks With Massive Upside Potential
The article highlights three biotech stocks with significant potential growth: Viking Therapeutics, ImmunityBio, and Maze Therapeutics, each showing promising clinical trial results and analyst optimism despite current market volatility.
Up 86% since February, promising Phase 1 results for rare disease treatment, analysts see potential for 2x stock growth
PositiveGlobeNewswire Inc.• Jason Coloma
Maze Therapeutics Appoints Misbah Tahir as Chief Financial Officer
Maze Therapeutics announced the appointment of Misbah Tahir as CFO, bringing over 20 years of financial experience in the biopharmaceutical industry. Tahir will support the company's growth strategy and upcoming clinical milestones for precision medicine treatments targeting kidney and metabolic diseases.
Positive sentiment due to strategic leadership appointment, strong financial position, and promising clinical pipeline with upcoming milestone data
PositiveGlobeNewswire Inc.• Maze Therapeutics
Maze Therapeutics Doses First Patient in Phase 2 HORIZON Clinical Trial Evaluating MZE829 as a Potential Treatment for APOL1 Kidney Disease
Maze Therapeutics has dosed the first patient in a Phase 2 clinical trial of its APOL1 inhibitor MZE829 for the treatment of APOL1 kidney disease. The trial aims to evaluate the drug's efficacy across a diverse patient population.
The article highlights Maze Therapeutics' progress in advancing a novel treatment for APOL1 kidney disease, a significant unmet medical need. The initiation of the Phase 2 trial and the potential for MZE829 to be a 'disease-modifying therapy' suggest the company is making promising advancements.
News and sentiment labels describe article tone and are provided for research purposes only. They are not trading recommendations or forecasts.
Trade Ranks App
Trade Ranks, LLC is not a registered investment adviser or broker-dealer. All rankings and AI reports are for informational and educational purposes only and are not personalized advice. Investing involves risk. Policy Portal
